News & Updates
Filter by Specialty:
Meeting gender-affirming needs tied to accessing HIV services among transgender people
Having met gender-affirming care needs among transgender people is associated with accessing HIV-related services in a community-led clinic, as shown in a Philippines study presented at IAS 2023.
Meeting gender-affirming needs tied to accessing HIV services among transgender people
16 Aug 2023
Dapagliflozin cuts risk of total HF events, CV deaths in HF patients
In a prespecified analysis of the DELIVER* study, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the rate of total** heart failure (HF) events or cardiovascular (CV) deaths in HF patients with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF).
Dapagliflozin cuts risk of total HF events, CV deaths in HF patients
16 Aug 2023
Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC
In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.
Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC
16 Aug 2023
S-1 plus oxaliplatin on par with existing regimen for colorectal cancer treatment
Treatment with S-1, an oral fluoropyrimidine formulation similar to capecitabine, plus oxaliplatin (SOX) results in substantial improvements in overall response rate relative to capecitabine plus oxaliplatin (CapeOx) in patients with metastatic colorectal cancer, according to a Philippines study presented at the recent ESMO GI 2023.
S-1 plus oxaliplatin on par with existing regimen for colorectal cancer treatment
15 Aug 2023
Risk of hypertension higher with DTG in PLWH
In the secondary analysis of the NAMSAL and ADVANCE trials, first-line treatment with dolutegravir (DTG) was associated with significantly higher risks of treatment-emergent hypertension in people living with HIV (PLWH), especially in combination with tenofovir alafenamide (TAF).
Risk of hypertension higher with DTG in PLWH
15 Aug 2023
Another win for donanemab in TRAILBLAZER Alzheimer’s trial
In the phase III TRAILBLAZER-ALZ 2 study, donanemab significantly slowed clinical progression in individuals with early symptomatic Alzheimer’s disease* (AD) with amyloid and tau pathologies, demonstrating an important replication of the phase II findings.
